entertainment -WSS

entertainment

author：entertainment 2025-10-02 13:40:59 - browse：254

Anthony Fernandez holds a Wegovy injection, the ALP-1 agonist medication he uses to help curb his food cravings – Obesity medication and science coverage for STAT — A person holds a Wegovy injection pen. Kayana Szymczak for STAT

Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed to prevent heart problems, but policy experts said Medicare patients are still likely to encounter significant barriers getting access to the highly popular and expensive drug.

Medicare previously wasn’t reimbursing for Wegovy, since the federal payer is legally barred from covering weight loss drugs. But the Food and Drug Administration this month approved Wegovy for preventing heart problems in people with obesity and heart disease, leading many to suspect that Medicare would start covering the drug for this usage.

Makers of obesity drugs have been hoping that showing additional benefits beyond weight loss would induce more insurers to cover them. Medicare’s guidance, first reported Thursday, moves in that direction, but experts point out that the private insurers that administer Medicare’s prescription drug benefit — called Part D — can still choose to not include Wegovy on their formularies, especially if they think it would be too costly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Health Care Service Corp to buy Cigna Medicare Advantage plans

entertainment

WSS

States should stop sabotaging methadone treatment reform

There's no autism epidemic. It's an autism diagnosis epidemic

10 reasons why health care startups fail

States should stop sabotaging methadone treatment reform

Scientists boost immune system in aging mice by making it youthful

Boston competes with Raleigh

leisure time

entertainment

leisure time

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

23andMe had bad news about my health. I wish a person had delivered it

Why the world’s most expensive drug might be worth the price

In age of alternative facts, a scholarly course on calling out crap

Steward Health Care has deal to sell doctor network to UnitedHealth

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Syphilis numbers in the United States reach record heights

Virginia high school admissions case could be legal follow

Medicare Advantage insurers face 0.2% cut to 2025 payments

explore

White House pharmacy plagued with problems, investigation finds

Investment in vaccine development is lagging, report finds

Study says nonprofit hospitals fall short in charity care spending

Supreme Court mifepristone arguments center on docs' right to sue

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Vertex Pharmaceuticals may move headquarters in Boston

entertainment

leisure time

focus

hotspot